HC Wainwright Cuts SAB Biotherapeutics Price Target

Research firm lowers price target for biotech company's stock to $7.00 per share

Mar. 13, 2026 at 5:50am

Got story updates? Submit your updates here. ›

HC Wainwright, a research firm, has reduced its price target for shares of SAB Biotherapeutics (NASDAQ:SABS) from $9.00 to $7.00. The firm maintains a 'buy' rating on the stock, though other analysts have a more mixed view with one 'sell' rating and four 'buy' ratings. SAB Biotherapeutics is a clinical-stage biotech company focused on developing fully human polyclonal antibody therapies, primarily for infectious diseases.

Why it matters

The revised price target from HC Wainwright suggests the research firm sees less upside potential in SAB Biotherapeutics' stock compared to its previous outlook. This could impact investor sentiment and trading activity around the biotech company's shares. SAB's proprietary platform for generating human antibodies is an innovative approach, but the company's lead programs are still in clinical development, creating uncertainty around their commercial potential.

The details

In its research note, HC Wainwright cited the company's recent earnings report, which showed a larger-than-expected loss per share. Other analysts have a range of views on SAB Biotherapeutics, with one 'sell' rating, four 'buy' ratings, and an average price target of $10.00. The company is developing its antibody therapies using a unique 'Tc Bovine' platform that genetically engineers cattle to produce human antibodies.

  • SAB Biotherapeutics reported earnings on March 9, 2026.
  • HC Wainwright released its updated research note and price target on March 13, 2026.

The players

SAB Biotherapeutics

A clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota that focuses on developing fully human polyclonal antibody therapeutics using its proprietary 'Tc Bovine' platform.

HC Wainwright

A research firm that covers SAB Biotherapeutics and has reduced its price target for the company's stock.

Got photos? Submit your photos here. ›

The takeaway

The revised price target from HC Wainwright reflects ongoing uncertainty around SAB Biotherapeutics' pipeline and commercial prospects, despite the company's innovative approach to antibody development. Investors will be closely watching the progress of SAB's lead programs as they advance through clinical trials.